The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MPN 2026 | Advantages of the redefined MPN continuum vs traditional classification methods
Yu-Hung Wang, MD, PhD, National Taiwan University Cancer Center, Taipei City, Taiwan, discusses the advantages of an updated framework for defining the myeloproliferative neoplasms (MPNs) continuum over traditional classification methods. Dr Wang outlines that in this model, MPN scores and pseudo-analysis were used to provide insight into disease evolution trajectories, which can help to improve clinical decision-making. This interview took place at the ESH 11th Translational Research Conference on Myeloproliferative Neoplasms (ESH MPN 2026) in Estoril, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
